Thuja Capital

Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

InnoSIGN is a company focused on mRNA-based pathway activity profiling technology that aims to advance precision medicine by enhancing understanding of disease mechanisms. By leveraging a vast library of pathway activity profiles, InnoSIGN seeks to improve diagnostics and drug discovery processes. The company provides researchers with qPCR tests designed for decentralized use, which are available through its service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN aspires to transform the landscape of medical research and treatment by delivering more accurate insights into the causes of diseases.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

EsoBiotec is a Belgian biotechnology company dedicated to the discovery of innovative cancer therapies. The firm specializes in immunotherapies that aim to empower the human body to combat cancer through in vivo cell engineering. EsoBiotec focuses on developing cost-effective drugs and therapeutics, ensuring that patients have access to essential cancer treatments at lower costs. By prioritizing accessibility, the company seeks to improve the overall effectiveness of cancer care and enhance patient outcomes.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

EnCare Biotech B.V. is a biopharmaceutical company based in Utrecht, the Netherlands, established in 2014. It specializes in the development of therapeutic monoclonal antibodies, specifically targeting the EDA fragment of fibronectin, to prevent chronic heart failure following acute myocardial infarction. The company’s lead product focuses on providing innovative therapies to help healthcare professionals mitigate the risks of heart failure in patients. EnCare Biotech leverages a strong scientific foundation, collaborating with academic institutions and experts in various fields, including manufacturing, regulatory affairs, and clinical development. The management team possesses extensive experience in business development and finance, enabling the company to establish valuable partnerships and navigate complex regulatory environments. EnCare operates under a lean business model, maintaining core functions in-house while outsourcing operational activities to top-tier external providers, ensuring high standards of quality and efficiency in its development processes.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.

Cavadis is a Dutch biomedical company specializing in cardiovascular risk assessment. The company focuses on developing prognostic tests that identify patients at risk of cardiovascular diseases, including heart attacks and strokes. Cavadis has identified several novel biomarkers that are predictive of cardiovascular events and outperform traditional risk factors. Their aim is to create clinically meaningful risk stratification tools that enable physicians to personalize treatment plans, ultimately leading to improved patient outcomes. Through their innovative approach, Cavadis seeks to enhance the accuracy of cardiovascular risk assessment and support healthcare providers in delivering tailored medical care.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics specifically for pets and livestock. It has a proprietary platform that supports the creation of innovative treatments targeting various viral diseases. The company is advancing its pipeline of clinical and development stage candidates, including drugs intended for feline herpes and feline immunodeficiency virus. Through its research and development efforts, Okapi aims to provide veterinarians with the latest antiviral treatments, enhancing the standards of care for animal health. Targeting both companion animals and livestock, Okapi Sciences is positioned to make significant contributions to veterinary medicine with its novel technologies and strong academic partnerships.

Bioceros B.V. is a biopharmaceutical research and development contract organization based in Utrecht, the Netherlands, founded in 2003. The company specializes in the early pre-clinical development of recombinant proteins, particularly monoclonal antibodies. Bioceros provides a comprehensive range of technical and scientific services, including assay development, molecular biology, cell biology, immunology, protein expression, upscaling, fermentation, protein purification, and consulting. These services are aimed at biotech companies, academic institutions, and pharmaceutical firms, enabling them to access fully integrated programs from DNA to drug product. This approach supports the advancement of medicinal products and ultimately aids in addressing patient needs.

Cavadis is a Dutch biomedical company specializing in cardiovascular risk assessment. The company focuses on developing prognostic tests that identify patients at risk of cardiovascular diseases, including heart attacks and strokes. Cavadis has identified several novel biomarkers that are predictive of cardiovascular events and outperform traditional risk factors. Their aim is to create clinically meaningful risk stratification tools that enable physicians to personalize treatment plans, ultimately leading to improved patient outcomes. Through their innovative approach, Cavadis seeks to enhance the accuracy of cardiovascular risk assessment and support healthcare providers in delivering tailored medical care.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics specifically for pets and livestock. It has a proprietary platform that supports the creation of innovative treatments targeting various viral diseases. The company is advancing its pipeline of clinical and development stage candidates, including drugs intended for feline herpes and feline immunodeficiency virus. Through its research and development efforts, Okapi aims to provide veterinarians with the latest antiviral treatments, enhancing the standards of care for animal health. Targeting both companion animals and livestock, Okapi Sciences is positioned to make significant contributions to veterinary medicine with its novel technologies and strong academic partnerships.

Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.